Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Nitrofurantoin may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
e Nitrofurantoin
DO NOT TAKE Nitrofurantoin: if you are allergic to nitrofurantoin or any of the other ingredients in this medicine (listed in section 6) if you have kidney disease that seriously affects the kidneys (ask your doctor if you are not sure) if you suffer from porphyria (reduced red pigmentation in the blood) if you have deficiency in an enzyme called G6PD (glucose-6-phosphate dehydrogenase), which can quickly damage your red blood cells in infants under the age of 3 months if you have ever had a lung or liver reaction or a peripheral neuropathy (tingling, numbness or
weakness in the limbs) when using nitrofurantoin or other nitrofurans Tell your doctor if you are not sure about any of the above. Warnings and precautions Talk to your doctor or pharmacist before taking Nitrofurantoin. Talk to your doctor if you experience fatigue, yellowing of the skin or eyes, itching, skin rashes, joint pain, abdominal discomfort, feeling sick (nausea), vomiting, loss of appetite, dark urine and pale or grey-coloured stools. These may be symptoms of liver disorder. With long-term treatment, especially in elderly people, regular monitoring is required by the doctor in order to detect possible side effects as soon as possible. In some individuals with dark skin colour and of Afro-Caribbean, Mediterranean, Middle Eastern or Western Asian origin anaemia could develop during treatment. If you belong to this group and experience fatigue (feeling tired), dizziness and shortness of breath during treatment, stop taking this medicine and contact your doctor. If you experience a tingling sensation or numbness in your hands or feet during treatment or a weak feeling in your limbs, stop taking this medicine and contact your doctor. The chance of these side effects increases when, for example, your kidneys are not working well. If you have diabetes or anaemia, or a disease that causes severe weakness, or you have had allergic reactions before, tell your doctor. Complications in the lungs or liver may occur: see 'Possible side effects'. If such complications arise, the use of Nitrofurantoin must be stopped immediately. Other medicines and Nitrofurantoin Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Some of these medicines may change the effect of Nitrofurantoin. Antacids for indigestion (e.g. magnesium trisilicate). Medicines for gout (e.g. probenecid or sulfinpyrazone). Medicines that slow the passage of food through the stomach (e.g. atropine, hyoscine). Medicines for raised pressure in the eye (glaucoma), such as carbonic anhydrase inhibitors (e.g. acetazolamide). Medicines that make the urine less acidic (e.g. potassium citrate mixture). Medicines for infections, known as quinolones. Typhoid vaccine, which is given for the prevention of typhoid. If you are in doubt about any of these medicines, ask your doctor or pharmacist. Nitrofurantoin can influence the results of a number of tests for the determination of glucose in the urine. Nitrofurantoin with food and drink Nitrofurantoin should always be taken with food or milk. Taking this medicine with food or milk makes it work more effectively and will help to prevent stomach complaints. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. As far as it is known nitrofurantoin may be used in pregnancy. However, it should not be used during
labour or delivery because there is a possibility that use at this stage may harm the baby. If you want to breast-feed, please ask your doctor before taking this medicine. Driving and using machines Nitrofurantoin may cause dizziness and drowsiness. Do not drive or operate machinery if you are affected in this way until such symptoms go away. Nitrofurantoin contains lactose If you have been told by your doctor that you are intolerant to some sugars and have to avoid them, contact your doctor before taking this medicine. 3.
Nitrofurantoin
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Nitrofurantoin capsules are taken by mouth: swallow them during meals or with some milk or yogurt. This way this medicine is better tolerated and leads to the best results. The recommended dose is: Acute uncomplicated lower urinary tract infections: For adults and children over 12 years, a dose of 1 capsule of 50 mg, 4 times per day (1 capsule with each meal and 1 before bedtime). General use for 5 to 7 days or at least 3 days after no infection is detectable in the urine. In girls aged 5 to 12 years: 3 to 6 mg/kg body weight per day divided over 4 doses per day, also for 7 days or at least 3 days after no infection is detectable in the urine. This pharmaceutical form (capsules) may not be suitable for use in children in this age group. Short-term prophylaxis for urinary tract surgery and inserting bladder catheters (adults and children over 12 years): 4 x 50 mg per day on the day of the procedure and for 3 days after. Long-term treatment of urinary tract infections (adults and children over 12 years): 1 capsule of 50 or 100 mg per day usually in the evening before bedtime and after you last pass urine: for a maximum of 6 months. When treatment is started, the symptoms can quickly decrease, usually within 1-3 days. Finally they usually disappear completely. Nevertheless, you should always completely finish the full course of treatment. The symptoms may have disappeared, but that does not mean that all the bacteria have already been killed. If you stop too early, the symptoms can return quickly, which is uncomfortable for you and medically undesirable. If after 3 days the discomfort is not gone, or is not greatly reduced, then visit your doctor again. If you take more Nitrofurantoin than you should Ask your doctor or pharmacist immediately or go to the emergency department of the nearest hospital. Always take any leftover capsules with you, as well as the container and label, so that the medical staff knows what you have taken. If you forget to take Nitrofurantoin Do not worry. If you remember later that day, take that day's dose as usual. If you miss a whole day's
dose take the normal dose on the next day. Do not take a double dose to make up for a forgotten dose. If you are not sure ask your doctor or pharmacist. If you stop taking Nitrofurantoin Your doctor will tell you how long to take the treatment. Do not stop earlier than you are told, even if you feel better. Speak to your doctor, pharmacist or nurse, if you are thinking about stopping treatment early. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 4.
Like all medicines, this medicine can cause side effects, although not everybody gets them. All medicines can cause allergic reactions, although serious allergic reactions are rare. If you have sudden shortness of breath, difficulty breathing, swelling of the eyelids, face or lips, skin rash or itching (especially affecting your whole body), stop taking this medicine and go to a doctor immediately. If you experience any of the side effects listed below, stop taking Nitrofurantoin and see your doctor. Nitrofurantoin can occasionally discolour the urine from dark yellow to brown. This is normal and disappears after the treatment. If you notice any of the following side effects, tell your doctor immediately: Problems with your lungs. This can happen quickly, within one week after the start of treatment, or very slowly, especially in the elderly and can lead to fever, shivering, coughing and shortness of breath associated with pneumonia and tissue damage. Nitrofurantoin can cause liver inflammation, resulting in jaundice (yellow discoloration of the skin or of the white of the eyes). in some patients the blood cells are affected, leading to bruises, delayed blood clotting, sore throat, fever, anaemia and susceptibility to colds or persistent common cold increased pressure in the skull (which causes severe headaches) severe allergic skin reactions (DRESS syndrome) various skin reactions, including skin peeling (flakes), redness skin rash or fever accompanied by a rapid heartbeat and severe blistering Very common (may affect more than 1 in 10 people): urinary tract infection by bacteria that are not susceptible to nitrofurantoin short-term hair loss Rare (may affect up to 1 in 1,000 people): loss of appetite feeling sick (nausea) loss of consciousness (collapse) bluish or grayish colour of the skin, nails, lips or around the eyes (cyanosis) Not known (frequency cannot be estimated from the available data): headaches diarrhoea stomach pain, being sick (vomiting) dizziness, drowsiness
The nerves can be affected, resulting in changes in sensitivity and the use of the muscles. In addition, headaches, extreme changes in mood or mental condition, confusion, weakness, poor vision. a feeling or state of intense excitement and happiness (euphoria) other reactions may include: inflammation of the salivary glands (causing pain in the face), inflammation of the pancreas (causing severe abdominal pain), joint pain inflammation in the blood vessels of the skin liver inflammation due to abnormal antibodies against liver cells (autoimmune hepatitis) inflammation of small blood vessel walls, causing skin lesions liver inflammation due to the immune system turning against liver cells inflammation of kidney tissue surrounding tubules, causing kidney problems Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. 5.
Nitrofurantoin
Keep this medicine out of the sight and reach of children. This medicine does not require any special storage conditions. Do not use this medicine after the expiry date which is stated on the carton and blister. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment. 6.
What Nitrofurantoin contains The active substance is nitrofurantoin. Nitrofurantoin capsules are available in two strengths, containing either 50 mg or 100 mg of nitrofurantoin. The other ingredients: Capsule content; maize starch, lactose monohydrate (see section 2 'Nitrofurantoin contains lactose'), talc. Capsule shell; titanium dioxide (E171), gelatin, yellow iron oxide (E172). What Nitrofurantoin looks like and contents of the pack Nitrofurantoin 50 mg hard capsule is a hard gelatin capsule with a yellow cap and white body. Nitrofurantoin 100 mg hard capsule is a hard gelatin capsule with a yellow cap and yellow body. Nitrofurantoin is available in blister packs containing 20 or 30 capsules and a bottle pack of 500 capsules. Not all pack sizes may be marketed. Marketing Authorisation Holder Mylan Potters Bar Hertfordshire EN6 1TL
United Kingdom Manufacturer(s) IASIS PHARMACEUTICALS HELLAS ΑΒΕΕ, 137, Filis Ave, Kamatero, Attiki, 13451, Greece. IASIS PHARMACEUTICALS HELLAS S.A. – KOROPI, Archimidous Street, Koropi Attikis, 19 400 Greece This leaflet was last revised in July 2022.
Nitrofurantoin 50 mg Hard Capsules comes as capsule containing 50mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Nitrofurantoin 50 mg Hard Capsules is nitrofurantoin.
Medicines with the same active substance, strength and form include: Nitrofurantoin 50 mg Capsules, Nitrofurantoin 50 mg capsules, Nitrofurantoin 50 mg hard capsules. In total there are 5 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Nitrofurantoin 50 mg Hard Capsules, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Nitrofurantoin is indicated in diseases of the urinary tract that are caused by micro-organisms sensitive to nitrofurantoin (see section 5.1).
• In acute uncomplicated lower urinary tract infections;
• For short-term prophylaxis after surgical procedures, transurethral interventions, catheterization, cystoscopy and indwelling catheter;
• For long-term treatment of urinary tract infections up to 6 months; longer than 6 months only if the benefits clearly outweigh the potential risks. In view of the side effects, long-term therapy should only be used if no suitable alternative is available (see section 4.4).
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Posology
Treatment of acute uncomplicated lower urinary tract infections
Adults and children aged over 12 years: one 50 mg capsule 4 times a day.
General use: 5 to 7 days or at least 3 days after no infection is detectable in the urine.
In girls aged 5 to 12 years: the usual dose is 3 to 6 mg/kg body weight per day divided into 4 doses; for 7 days or at least 3 days after no infection is detectable in the urine.
This pharmaceutical form (capsules) may not be suitable for use in children in this age group.
Short-term prophylaxis for urinary tract surgery
Adults and children from 12 years of age: 50 mg 4 times per day on the day of surgery and for 3 days after.
Long-term treatment of urinary tract infections
Adults and children from 12 years: 50 to 100 mg once a day, usually in the evening before sleep.
Method of administration
For oral use.
This medicinal product should always be taken with food or milk. Taking Nitrofurantoin with a meal improves absorption and is important for optimal efficacy.
Nitrofurantoin is contraindicated:
• for patients with hypersensitivity to the active substance or to any of the excipients listed in section 6.1
• for patients with renal impairment (eGFR below 45 ml/min) or with an increased serum creatinine
• for patients with G6PD deficiency
• for patients with acute porphyria
• for infants younger than three months because of the theoretical possibility of haemolytic anaemia in the foetus or in the newborn (less than 3 months old) due to immature erythrocyte enzyme systems
• for patients who have previously had a lung or liver reaction other than a peripheral neuropathy after use of nitrofurantoin or other nitrofurans.
Prolonged use of Nitrofurantoin is not recommended. During nitrofurantoin treatment there may be lung and liver complications that could be life-threatening (see section 4.8). If this happens treatment should be stopped immediately and the necessary measures should be taken.
Acute, subacute and chronic pulmonary reactions have been observed in patients treated with nitrofurantoin. If these reactions occur, nitrofurantoin must be discontinued immediately.
Chronic pulmonary reactions (including pulmonary fibrosis and diffuse interstitial pneumonitis) can develop insidiously and can often occur in elderly patients. Close monitoring of the lung disease of patients receiving long-term therapy is indicated (especially in the elderly).
Hepatotoxicity
Hepatic reactions, including hepatitis, autoimmune hepatitis, cholestatic jaundice, chronic active hepatitis and hepatic necrosis, occur rarely. Fatalities have been reported. The onset of chronic active hepatitis may be insidious and patients should be monitored periodically for changes in biochemical tests that would indicate liver injury. If hepatitis occurs, this medicinal product should be withdrawn immediately and appropriate measures should be taken.
Existing conditions can mask pulmonary and hepatic side effects. Caution should be exercised when nitrofurantoin is used in patients with pulmonary diseases, disturbed hepatic function, neurological disorders and allergic diathesis.
Peripheral neuropathy, which can become serious or irreversible, has occurred (usually within two months) and can become life-threatening. Therefore, treatment should be discontinued at the first signs of neural infection (paraesthesia, weakness). Conditions such as renal insufficiency, anaemia, diabetes mellitus, alcoholism, electrolyte disorder, vitamin B deficiency (especially folate deficiency) and exhaustive conditions increase the risk of developing peripheral neuropathy.
Urine can be coloured yellow or brown after taking nitrofurantoin. Patients taking nitrofurantoin can test false positive for urine glucose (if tested for urine reducing substances).
Nitrofurantoin should be discontinued if there is evidence of haemolysis in suspected persons of glucose-6-phosphate dehydrogenase deficiency (ten percent of individuals with dark skin colour of Afro-Caribbean origin and a small percentage of ethnic groups coming from the Mediterranean, Middle Eastern or Western Asian origin suffer from a G6PD deficiency).
Excipients
This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
The effect of other medicinal products on nitrofurantoin:
• Food or medicinal products that delays gastric emptying increase the bioavailability of nitrofurantoin, probably due to better dissolution in the gastric juice.
• Carbonic anhydrase inhibitors and alkalising agents can reduce the antibacterial activity of nitrofurantoin.
• Magnesium trisilicate co-administered with nitrofurantoin reduces the absorption of nitrofurantoin.
• There may be an antagonism between quinolones and nitrofurantoin: simultaneous application is not recommended.
• Probenecid and sulfinpyrazone can reduce the renal clearance of nitrofurantoin.
The effect of nitrofurantoin on other medicines/laboratory tests:
• Typhoid fever vaccine (oral): antibacterial agents make the oral typhoid fever vaccine ineffective.
• Nitrofurantoin can affect certain laboratory tests. False positive results or incorrect high reading can occur with urinary glucose tests based on the reduction of copper sulphate, such as Benedict's reagent and Clinitest (Ames). However, there is no interference with the Clinistix test.
Pregnancy
A large amount of data in pregnant women has no teratogenicity or foetal/neonatal toxicity. Animal studies do not show reproductive toxicity at clinically relevant doses. If prescribed by a doctor, nitrofurantoin can be used during pregnancy.
However, because of the possible risk of haemolysis of immature red blood cells in the baby, it is best not to be administered just before and during the delivery.
Breast-feeding
Nitrofurantoin is excreted in breast milk. The quantities in milk are so small that it is unlikely that these amounts can cause haemolytic anaemia in a G6PD-deficient infant. Nitrofurantoin can be used during breastfeeding.
Fertility
In men, a temporary stoppage in spermatogenesis and reduced sperm counts were observed at supratherapeutic doses. Clinical doses are not associated with male infertility. No reduced fertility was observed in animal studies. In rats, at high doses observed a temporary stoppage in spermatogenesis.
Nitrofurantoin may cause dizziness and drowsiness. If this happens the patient should not drive or operate machinery until the symptoms disappear.
Reported adverse reactions for nitrofurantoin are listed below according to organ system class.
The frequency of the adverse reactions listed below is defined according to the following convention: very common (≥1/10), rare (≥1/10,000 to <1/1,000), not known (frequency cannot be estimated from the available data).
MedDRA System Organ Class (SOC)
Frequency
Side effects
Infections and infestations
Not known
Sialadenitis.
Blood and lymphatic system-diseases
Rare
Agranulocytosis, eosinophilia, leucopenia, granulocytopenia, thrombocytopenia, aplastic anaemia and megaloblastic anaemia1.
Immune system disorders
Rare
Exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome.
Not known
Maculo-papular rash, rash erythematous, eczema, urticaria, angioedema. Lupus syndrome (associated with lung reactions), anaphylactic reactions, DRESS syndrome, cutaneous vasculitis.
Metabolism and nutrition disorders
Rare
Anorexia.
Psychiatric disorders 2
Not known
Depression, euphoria, confusion, psychotic reactions, headaches2.
Nervous system disorders
Very common
Idiopathic intracranial hypertension.
Not known
Peripheral motor neuropathy, peripheral sensory neuropathy. Neuritis optics. Nystagmus, dizziness, somnolence.
Cardiac disorders
Rare
Circulatory collapse and cyanosis.
Respiratory, thoracic and mediastinal conditions
Not known
Acute lung reactions3, fever, chills4, chest pain, dyspnoea, cough, lung infiltration with consolidation or pleural effusion5 and eosinophilia.Subacute lung reactions, fever and eosinophilia.Chronic lung reactions, fever, chills, cough and dyspnoea6.
Gastrointestinal disorders
Rare
Nausea.
Not known
Vomiting, abdominal pain, diarrhoea, pancreatitis.
Hepatobiliary disorders
Rare
Cholestatic icterus and chronic hepatitis7.
Not known
Autoimmune hepatitis.
Skin and subcutaneous tissue disorders
Very common
Short-lived alopecia.
Renal and urinary disorders
Very common
Superinfections by fungi or resistant organisms (i.e. Pseudomonas).
Not known
Interstitial nephritis
Congenital, familial and genetic disorders
Rare
Haemolytic anaemia/G6PD deficiency anaemia.
General disorders and administration site conditions
Not known
Asthenia, arthralgia.
1 Treatment should be discontinued when the blood count returns to normal.2 Treatment should be discontinued at the first signs of neurological and/or psychological involvement.3 If any of the following respiratory reactions occur, the use of this medicinal product should be stopped.4 Acute pulmonary reactions usually occur within the first week of treatment and are reversible after discontinuation of treatment.5 Demonstrated through X-ray diagnosis.6 Chronic pulmonary reactions are rare in patients receiving continuous treatment for 6 months or more get longer and are more common in older patients.7 Fatalities are reported. Cholestatic icterus is generally associated with short-term treatment (usually up to 2 weeks). Chronic active hepatitis, which occasionally leads to necrosis, is generally associated with long-term treatment (usually 6 months). Treatment should be discontinued at the first signs of hepatotoxicity. See section 4.4.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms
Symptoms and signs of overdose include gastric irritation, nausea and vomiting.
Management
There is no known specific antidote. However, nitrofurantoin can be haemodialysed in cases of recent ingestion. Standard treatment is by induction of emesis or by gastric lavage within one hour after ingestion. Monitoring of full blood count, liver function and pulmonary function tests are recommended. A high fluid intake should be maintained to promote urinary excretion of this medicinal product.
Ask anything about Nitrofurantoin 50 mg Hard Capsules. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.